Back to search
FDAFDA · Food and drugs·Recall number D-0098-2018

Liothyronine Sodium Tablets, USP 25 mcg ,100-count bottles, Rx Only, Distributed by Perrigo Minneapolis, MN 55427, NDC 0574-0222-01

Published December 6, 2017 · Recall initiated: November 9, 2017

Summary

FDA records drug Class II recall D-0098-2018, published December 6, 2017 and initiated November 9, 2017. Recalling firm: Mayne Pharma Inc; Status: Terminated; Reported quantity: 11,364 bottles; Lot: Lot: #:16F649, Exp: May 2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mayne Pharma Inc
Distributor
Nationwide within USA
Lot
Lot: #:16F649, Exp: May 2018
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Liothyronine Sodium Tablets, USP 25 mcg ,100-count bottles, Rx Only, Distributed by Perrigo Minneapolis, MN 55427, NDC 0574-0222-01 recalled?

Yes. FDA published recall D-0098-2018 on December 6, 2017. Reported hazard: Failed Dissolution Specifications.

What should I do if I have this product?

Voluntary: Firm initiated · Letter